Cross-Seeding of Misfolded Proteins: Implications for Etiology and Pathogenesis of Protein Misfolding Diseases

PLoS Pathogens

Volumn 9, Issue 9, 2013, Pages

  Morales, Rodrigo ^a   Moreno Gonzalez, Ines ^a   Soto, Claudio ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A2; TAU PROTEIN; PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CREUTZFELDT JAKOB DISEASE; GENETIC PREDISPOSITION; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOGOLD ELECTRON MICROSCOPY; LEWY BODY; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN POLYMERIZATION; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DISEASE MODEL; PATHOPHYSIOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN FOLDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEINS; PROTEOSTASIS DEFICIENCIES;

EID: 84884683227     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003537     Document Type: Article

References (38)

1. Soto C, (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 4: 49-60.
2. Jarrett JT, Lansbury PT Jr, (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055-1058.
3. Soto C, Estrada L, Castilla J, (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31: 150-155.
4. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, et al. (1994) Cell-free formation of protease-resistant prion protein. Nature 370: 471-474.
5. Morales R, Green KM, Soto C, (2009) Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets 8: 363-371.
6. Soto C, (2012) Transmissible proteins: expanding the prion heresy. Cell 149: 968-977.
7. Jucker M, Walker LC, (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70: 532-540.
8. Brundin P, Melki R, Kopito R, (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11: 301-307.
9. Aguzzi A, (2009) Cell biology: beyond the prion principle. Nature 459: 924-925.
10. Westermark GT, Westermark P, (2010) Prion-like aggregates: infectious agents in human disease. Trends Mol Med 16: 501-507.
11. Krebs MR, Morozova-Roche LA, Daniel K, Robinson CV, Dobson CM, (2004) Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci 13: 1933-1938.
12. O'Nuallain B, Williams AD, Westermark P, Wetzel R, (2004) Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 279: 17490-17499.
13. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, et al. (2010) Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 30: 4528-4535.
14. Guo JP, Arai T, Miklossy J, McGeer PL, (2006) Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A 103: 1953-1958.
15. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, et al. (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 3: e3135 doi:10.1371/journal.pone.0003135.
16. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM, (2010) Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30: 7281-7289.
17. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R, (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 31: 1153-1162.
18. Yan J, Fu X, Ge F, Zhang B, Yao J, et al. (2007) Cross-seeding and cross-competition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. Am J Pathol 171: 172-180.
19. Gotz J, Chen F, Van Dorpe J, Nitsch RM, (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495.
20. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491.
21. Ferrer I, (2004) Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. Neurotox Res 6: 469-475.
22. Hamilton RL, (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10: 378-384.
23. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, et al. (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98: 12245-12250.
24. Johan K, Westermark G, Engstrom U, Gustavsson A, Hultman P, et al. (1998) Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci U S A 95: 2558-2563.
25. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P, (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5: 64-74.
26. Sims-Robinson C, Kim B, Rosko A, Feldman EL, (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6: 551-559.
27. Biessels GJ, Kappelle LJ, (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33: 1041-1044.
28. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, et al. (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24: 2716-2726.
29. Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, et al. (2010) Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS ONE 5: e15725 doi:10.1371/journal.pone.0015725.
30. Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, et al. (2001) Prion protein expression in senile plaques in Alzheimer's disease. Acta Neuropathol (Berl) 101: 49-56.
31. Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, et al. (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5: 347-354.
32. Tsuchiya K, Yagishita S, Ikeda K, Sano M, Taki K, et al. (2004) Coexistence of CJD and Alzheimer's disease: an autopsy case showing typical clinical features of CJD. Neuropathology 24: 46-55.
33. Miyazono M, Kitamoto T, Iwaki T, Tateishi J, (1992) Colocalization of prion protein and beta protein in the same amyloid plaques in patients with Gerstmann-Straussler syndrome. Acta Neuropathol (Berl) 83: 333-339.
34. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330: 1774.
35. Tanzi RE, Moir RD, Wagner SL, (2004) Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43: 605-608.
36. Gidalevitz T, Kikis EA, Morimoto RI, (2010) A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr Opin Struct Biol 20: 23-32.
37. Barnes DE, Yaffe K, (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10: 819-828.
38. Bertram L, Lill CM, Tanzi RE, (2010) The genetics of Alzheimer disease: back to the future. Neuron 68: 270-281.